Ultimovacs ASA (OSL:ULTI) Total Liabilities : kr48.41 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Total Liabilities?

Ultimovacs ASA's Total Liabilities for the quarter that ended in Mar. 2024 was kr48.41 Mil.

Ultimovacs ASA's quarterly Total Liabilities increased from Sep. 2023 (kr59.38 Mil) to Dec. 2023 (kr69.65 Mil) but then declined from Dec. 2023 (kr69.65 Mil) to Mar. 2024 (kr48.41 Mil).

Ultimovacs ASA's annual Total Liabilities declined from Dec. 2021 (kr62.38 Mil) to Dec. 2022 (kr60.32 Mil) but then increased from Dec. 2022 (kr60.32 Mil) to Dec. 2023 (kr69.65 Mil).

Ultimovacs ASA Total Liabilities Historical Data

The historical data trend for Ultimovacs ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Total Liabilities Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

33.41

41.34

62.38

60.32

69.65

Ultimovacs ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															72.03	53.89	59.38	69.65	48.41

Ultimovacs ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ultimovacs ASA's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	56.109	+	(1.886	+	11.652
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	69.65

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	349.039	-	279.392
	=	69.65

Ultimovacs ASA's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	35.224	+	(1.649	+	11.539
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	48.41

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	307.618	-	259.206
	=	48.41

Ultimovacs ASA Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.